How CRISPR Is Rewriting Medicine Faster Than Regulators Can Follow
June 5, 2026 · Frisian News
Gene-editing companies deploy CRISPR treatments in clinics and overseas markets while regulatory agencies struggle to keep pace with the science. The gap between innovation and approval creates both opportunity and risk for patients.
Editas Medicine reported that its CRISPR treatment for a rare eye disorder had restored sight in a small number of patients who were clinically blind. The company is pushing for near-term FDA approval. But regulators have approved only a few CRISPR therapies worldwide, while dozens more are in clinical trials or already operating in less regulated countries. The pace mismatch is not accidental. It reflects how quickly gene-editing technology moves compared to how bureaucracies assess safety.
China and India have moved faster than the West. Chinese clinics run CRISPR trials that would face years of regulatory review in the United States or Europe. Some trials operate in gray zones, offering experimental treatments to wealthy patients before data proves safety or efficacy. This creates a real problem: wealthy people get access to unproven therapies while ordinary citizens in regulated countries must wait. The incentive structure favors speed over caution, and companies know regulators cannot reject treatments that have already helped patients abroad.
The FDA and European Medicines Agency struggle with a fundamental question they have not solved. How do you assess a one-time genetic edit that its makers claim will work for a patient's entire life? Traditional drug trials run for years. Gene therapy trials cannot, because the treatment happens once. Regulators ask for long-term data that does not yet exist. Editas and competitors argue this standard is outdated. They point to real patients with real diseases who could benefit today.
Money flows to whoever moves fastest. Editas, CRISPR Therapeutics, Intellia, and Beam Therapeutics have raised billions in venture capital and public markets. These companies can afford to run trials in multiple countries at once. They hire regulators' own former staff as consultants. They lobby for faster pathways. Traditional pharmaceutical companies, bound by older approval rules, cannot compete. This reshapes what gets treated: CRISPR companies focus on rare genetic diseases with small patient populations, where approval comes faster. Common diseases like diabetes or heart disease require bigger trials and wait longer, if they get pursued at all.
The real question nobody wants to answer: who decides if speed is worth the risk? Regulators assume patients want to wait for perfect data. Patients with dying vision or degenerative disease assume they want to try something now. Right now, money and geography decide. That is not a system. It is chaos dressed up as innovation.
Published June 5, 2026 · Frisian News